# Comparison of Biphozyl® and Phoxilium® as a Replacement Fluid During CVVH for AKI in Adults and Their Effects on pH-, Bicarbonate-levels and Respiratory Situation

> **NCT04071171** · PHASE2 · COMPLETED · sponsor: **Medical University Innsbruck** · enrollment: 88 (actual)

## Conditions studied

- Critically Ill
- Acute Kidney Injury
- Renal Replacement Therapy
- Continuous Renal Replacement Therapy
- Continuous Veno-Venous Hemofiltration
- Replacement Fluid
- Phoxilium
- Biphozyl
- Anticoagulation
- Regional Citrate Anticoagulation

## Interventions

- **DRUG:** CVVH with Phoxilium® in the first 48h after randomization
- **DRUG:** CVVH with Biphozyl® in the first 48h after randomization
- **DRUG:** CVVH with Phoxilium® in the second 48h after randomization (after previous 48h with Biphozyl®)
- **DRUG:** CVVH with Biphozyl® in the second 48h after randomization (after previous 48h with Phoxilium®)

## Key facts

- **NCT ID:** NCT04071171
- **Lead sponsor:** Medical University Innsbruck
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-01
- **Primary completion:** 2023-11-15
- **Final completion:** 2024-03-11
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2024-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04071171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04071171, "Comparison of Biphozyl® and Phoxilium® as a Replacement Fluid During CVVH for AKI in Adults and Their Effects on pH-, Bicarbonate-levels and Respiratory Situation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04071171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*